3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
It's not always a good idea to chase trends in a bull market, but sometimes the new wave of promising companies is more than a fad. In the biotech and pharma industries, right now is an exciting time, and there's reason to believe that the popular players of today will be strong investments for more than just a few months.
There are three companies in particular that you should know about, so let's cover each one below.
Vertex Pharmaceuticals (NASDAQ: VRTX) has a few different drivers that could power it to success during this bull market. First, there's the ongoing launch of its gene therapy Casgevy, which is a cure or near-cure for sickle cell disease (SCD) and beta thalassemia, a pair of rare hereditary disorders of the blood. That's a part of why analysts are expecting the company to bring in an average of $10.7 billion in sales this year.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
The stock is one of the favorites of our community with 44 Buy predictions and 2 Sell predictions.
With a target price of 405 € there is a slightly positive potential of 3.93% for Vertex Pharmaceuticals Inc. compared to the current price of 389.7 €.
